RedHill Biopharma Director Resigns

Ticker: RDHL · Form: 6-K · Filed: Jun 6, 2024 · CIK: 1553846

Redhill Biopharma Ltd. 6-K Filing Summary
FieldDetail
CompanyRedhill Biopharma Ltd. (RDHL)
Form Type6-K
Filed DateJun 6, 2024
Risk Levellow
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: board-member-resignation, corporate-governance, filing-update

TL;DR

RedHill Biopharma board member Alla Felder has resigned.

AI Summary

On June 4, 2024, Ms. Alla Felder submitted her resignation from the board of directors of RedHill Biopharma Ltd. The company, headquartered at 21 Ha'arba'a Street, Tel Aviv, Israel, filed this report on June 6, 2024.

Why It Matters

A board member's resignation can signal internal changes or strategic shifts within a company, potentially impacting its future direction.

Risk Assessment

Risk Level: low — This filing is a routine notification of a board member's resignation and does not contain information that inherently increases risk.

Key Players & Entities

  • RedHill Biopharma Ltd. (company) — Registrant
  • Alla Felder (person) — Resigning Board Member
  • June 4, 2024 (date) — Date of resignation submission
  • June 6, 2024 (date) — Filing date
  • 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (address) — Company Headquarters

FAQ

Who is RedHill Biopharma Ltd.?

RedHill Biopharma Ltd. is a pharmaceutical preparations company incorporated in Israel, with its principal executive offices located at 21 Ha'arba'a Street, Tel Aviv.

What is the purpose of this Form 6-K filing?

This Form 6-K is a report of a foreign private issuer filed for the month of June 2024, specifically to announce that Ms. Alla Felder submitted her resignation to the board of directors on June 4, 2024.

When did Ms. Alla Felder submit her resignation?

Ms. Alla Felder submitted her resignation to the board of directors on June 4, 2024.

What is the filing date of this report?

This report was filed on June 6, 2024.

Does RedHill Biopharma file annual reports under Form 20-F or 40-F?

RedHill Biopharma Ltd. files annual reports under Form 20-F, as indicated by the checkmark next to it.

Filing Stats: 419 words · 2 min read · ~1 pages · Grade level 8.4 · Accepted 2024-06-06 09:00:06

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: June 6, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.